^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Enweida (envafolimab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
TRACON Pharmaceuticals Announces Fast Track Designation By The FDA For Envafolimab For The Treatment Of The Soft Tissue Sarcoma Subtypes Of UPS And MFS
Published date:
09/14/2022
Excerpt:
TRACON Pharmaceuticals...announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy.
